| Literature DB >> 30891123 |
Christa C Chrovian1, Akinola Soyode-Johnson1, Jessica L Wall1, Jason C Rech1, Jeff Schoellerman1, Brian Lord1, Kevin J Coe1, Nicholas I Carruthers1, Leslie Nguyen1, Xiaohui Jiang1, Tatiana Koudriakova1, Bartosz Balana1, Michael A Letavic1.
Abstract
Herein, we disclose a series of selective GluN2B negative allosteric modulators containing a 1H-pyrrolo[3,2-b]pyridine core. Lead optimization efforts included increasing brain penetration as well as decreasing cytochrome P450 inhibition and hERG channel binding. The series was also optimized to reduce metabolic turnover in human and rat. Compounds 9, 25, 30, and 34 have good in vitro GluN2B potency and good predicted absorption, but moderate to high projected clearance. They were assessed in vivo to determine their target engagement. All four compounds achieved >75% receptor occupancy after an oral dose of 10 mg/kg in rat. Compound 9 receptor occupancy was measured in a dose-response experiment, and its ED50 was found to be 2.0 mg/kg.Entities:
Year: 2019 PMID: 30891123 PMCID: PMC6421534 DOI: 10.1021/acsmedchemlett.8b00542
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345